Evotec (NASDAQ:EVO) Price Target Cut to $8.00

Evotec (NASDAQ:EVO) had its target price trimmed by HC Wainwright from $11.00 to $8.00 in a report issued on Thursday morning, Benzinga reports. The firm currently has a buy rating on the stock.

EVO has been the topic of a number of other research reports. Deutsche Bank Aktiengesellschaft lowered Evotec from a hold rating to a sell rating in a research report on Thursday, August 8th. Morgan Stanley cut Evotec from an overweight rating to an equal weight rating and reduced their target price for the company from $15.00 to $6.00 in a report on Monday, July 29th.

Evotec Stock Performance

Shares of NASDAQ:EVO opened at $3.26 on Thursday. The company has a current ratio of 1.86, a quick ratio of 1.79 and a debt-to-equity ratio of 0.43. Evotec has a 52 week low of $2.85 and a 52 week high of $12.40. The firm’s fifty day moving average is $4.47 and its 200-day moving average is $5.84.

Institutional Trading of Evotec

Institutional investors have recently bought and sold shares of the company. Quadrant Capital Group LLC bought a new position in shares of Evotec in the 4th quarter worth about $25,000. Vanguard Personalized Indexing Management LLC bought a new stake in Evotec in the second quarter worth approximately $87,000. Cetera Advisors LLC acquired a new position in Evotec in the first quarter valued at approximately $188,000. DCF Advisers LLC lifted its stake in Evotec by 140.5% in the second quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after buying an additional 67,156 shares during the period. Finally, Optiver Holding B.V. boosted its holdings in shares of Evotec by 643.1% during the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after buying an additional 69,936 shares in the last quarter. Institutional investors own 5.81% of the company’s stock.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.